IQM Announces Major Upgrade to Resonance Quantum Cloud Platform With New Software Development Kit
IQM Quantum Computers, a global leader in building quantum computers, today announced a major upgrade to its quantum computing cloud platform, IQM Resonance, to accelerate the development of quantum algorithms with new software tools and provide end-users with a powerful new quantum system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250710268218/en/
IQM Resonance
The upgrade features Qrisp – a project started at Fraunhofer FOKUS – as the new default software development kit (SDK). Qrisp offers a highly powerful but easy to learn higher level programming interface for quantum developers and researchers. The Qrisp framework is and stays open source.
With the new software development kit becoming the default, IQM continues to support other popular quantum programming frameworks such as Qiskit, Cirq, Cuda Quantum, and TKET ensuring flexibility for all users. IQM’s comprehensive and open approach to quantum development builds a powerful foundation catering for both experienced and new quantum developers.
IQM has also appointed Raphael Seidel as Lead Quantum Software Engineer for Qrisp at IQM, to lead the next steps in Qrisp development beginning in October 2025. “Starting from grassroots efforts, Qrisp has demonstrated again and again that the underlying programming model brings serious performance advantages. From raw gate-counts to compiler scaling, Qrisp is state-of-the-art in quantum programming. A direct and strong integration into IQM’s physical quantum hardware will mark the next chapter of the framework and grants a strong head-start into the era of fault-tolerant quantum computers,” said Seidel.
Other key updates to the IQM Resonance platform include:
- Advanced error handling: The platform now supports error suppression and mitigation technologies. The first features include dynamical decoupling to protect qubits from environmental noise with readout error mitigation to improve the accuracy of experimental results coming next, allowing users to get more precise and reliable data from their quantum computations.
- Accelerated research with advanced libraries and resources: The platform also introduces a powerful Quantum Approximate Optimization Algorithm (QAOA) library. This key application library allows researchers to efficiently create, test, and optimize quantum circuits for complex optimization problems with a variety of different QAOA flavours, enabling rapid iteration on novel ideas.
- Expanded IQM Academy resources: IQM Academy now features comprehensive examples and tutorials for Qrisp and a new dedicated section on error reduction, also providing insights into IQM's upcoming Noise Robust estimation techniques. Furthermore, a dedicated lecture series using Qrisp on IQM hardware will be available soon.
- Pulse-Level Access: For advanced users seeking maximum experimental control, IQM Resonance now offers pulse-level access. This allows researchers to directly program pulse schedules, enabling fine-tuned experiments and the development of novel quantum operations.
To broaden access to its world-class platform, IQM also opens Starter tier, a free charge plan open for any end user. The new tier provides users with up to 30 credits per month on selected IQM quantum computers, removing barriers for students, researchers, and developers to start their quantum journey. To mark the debut of the Starter Tier and the availability of IQM Crystal 54, IQM is also extending access to the 54-qubit quantum computer to all Starter tier users for a limited time.
"We are entering a new era of utility for quantum computing, and these updates to IQM Resonance are a testament to our commitment to empowering the ecosystem," said Dr. Stefan Seegerer, Head of Product, Quantum Platform at IQM. "By making our Crystal 54-qubit system available, integrating error reduction techniques, and standardizing on Qrisp, we are providing the tools researchers and developers need to push the boundaries of what's possible. The new free Starter plan is a crucial step in our mission to make quantum technology accessible to everyone."
About IQM Quantum Computers:
IQM is a global leader in superconducting quantum computers. IQM provides both on-premises full-stack quantum computers and a cloud platform to access its computers. IQM customers include the leading high-performance computing centres, research labs, universities and enterprises which have full access to IQM's software and hardware. IQM has over 300 employees with headquarters in Finland and a global presence in France, Germany, Italy, Japan, Poland, Spain, Singapore, South Korea and the United States.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250710268218/en/
Contacts
Media contact:
Email: press@meetiqm.com
Mobile: +358504790845
www.meetiqm.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.meetiqm.com
%2F&esheet=54288575&newsitemid=20250710268218&lan=en-US&anchor=www.meetiqm.com&i
ndex=2&md5=94b812987bddc37aa87e9cf6cad6d86d
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th
WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release
Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release
Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom